Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial Spotlight
Non-small cell lung cancer
Phase II Trial: Dato-DXd, TROP2-directed ADC in advanced NSCLC
This Phase II study at AstraZeneca and select centers evaluates three sub-studies in advanced or metastatic NSCLC. It tests rilvegostomig—a Tigit and PD-1 bispecific mAb—with ramucirumab, a VEGFR2-directed antibody,…
NCT07098338 Exploratory - New trial Spotlight
Non-small cell lung cancer
Phase 2b trial of Visugromab, anti‐GDF15 monoclonal antibody, in metastatic NSCLC
CatalYm GmbH sponsors a multi-part Phase 2b study comparing visugromab with pembrolizumab, pemetrexed, and carboplatin versus placebo plus standard immunochemotherapy. The trial targets first-line treatment for…
NCT07098988 Exploratory - New trial
Lung cancer
Phase 1 Expansion: XeMRI-guided SBRT using xenon contrast for lung function imaging.
This study evaluates whether functionally adapted SBRT, guided by xenon-enhanced MRI, can better preserve lung function in lung cancer patients. Participants receive either standard SBRT with conventional imaging or…
NCT06925295 Exploratory - New trial Spotlight
Pancreatic cancer
Phase 2/3 trial of BMS-986504, a selective PRMT5 inhibitor, in metastatic pancreatic cancer.
The study evaluates safety and efficacy of BMS-986504 when combined with gemcitabine and nab-paclitaxel versus standard chemo plus placebo in a randomized design. It enrolls treatment-naïve patients with metastatic…
NCT07076121 Registrational - New trial Spotlight
Pancreatic cancer
Phase 1 Trial of OMO-103, a Myc Inhibitor, in Pancreatic Cancer
This early Phase 1 trial is assessing OMO-103, a dominant-negative MYC inhibitor (Omomyc miniprotein) that disrupts MYC–MAX, in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.…
NCT07089940 Exploratory - New trial
Pancreatic cancer
Phase 2 NALIRIFOX trial with liposomal irinotecan (topoisomerase I inhibitor) in pancreatic cancer.
Medical University of South Carolina is conducting a single-center, open-label, randomized Phase 2 trial comparing NALIRIFOX versus modified gemcitabine, nab-paclitaxel plus cisplatin in previously untreated patients…
NCT07076212 Exploratory - New trial
Pancreatic cancer
Phase 2 mFOLFIRINOX Trial with Irinotecan Topoisomerase I Inhibition in Metastatic PDAC
This Phase 2 study by the University of Miami investigates whether ctDNA monitoring can guide early treatment changes in patients with treatment-naive metastatic pancreatic ductal adenocarcinoma. Participants receive…
NCT07096362 Exploratory - New trial Spotlight
Brain and CNS tumors
Phase 1B SONALA-001 Protoporphyrin IX ROS activator with MRgFUS for recurrent glioblastoma
This Phase 1B study, sponsored by Mayo Clinic, evaluates the safety, optimal dosing, and preliminary effectiveness of SONALA-001 (a Protoporphyrin IX ROS activator small molecule) given with MR-guided focused…
NCT07076472 Exploratory - New trial Spotlight
Brain and CNS tumors
Phase 1 trial of GPC2 CAR-T cells targeting GPC2 in pediatric CNS embryonal tumors
This single-site, open-label Phase 1 trial at Stanford University evaluates feasibility, safety, and preliminary activity of autologous GPC2 CAR-T cells delivered via intracerebroventricular infusions in children and…
NCT07087002 First-in-human - New trial Spotlight
Brain and CNS tumors
Phase 1 Trial of M032 IL-12 Producing HSV Oncolytic Virus for Diffuse Midline Glioma
This trial led by MD Anderson Cancer Center evaluates a single intratumoral injection of M032, an IL-12 producing HSV oncolytic virus, in pediatric and adult patients with diffuse midline glioma following standard…
NCT07076498 First-in-human - New trial Spotlight
Brain and CNS tumors
Phase 1 CHAMP1ON: Nivolumab PD-1 Inhibitor for Pediatric High-Grade Glioma
University of Florida is conducting a Phase 1 trial to evaluate safety and feasibility of adjuvant and neoadjuvant ex vivo hematopoietic stem cells (exHSCs), an investigational cell therapy intended to support immune…
NCT07031765 First-in-human - New trial
Brain and CNS tumors
Phase 1 pilot study: Cerebral open flow microperfusion device for intraoperative brain tissue perfusion.
This feasibility study evaluates intraoperative cerebral open flow microperfusion using OFM catheters, tubing, and the MPP102-II pump during planned neurosurgical resection for patients with resectable Grade II-IV…
NCT07089758 First-in-human - New trial
Bladder and urothelial cancer
Phase II: Therapeutic plasma exchange + enfortumab vedotin (Nectin-4 ADC) + pembrolizumab vs standard therapy in metastatic urothelial/upper-tract cancer
This randomized Mayo Clinic study tests whether a TPE lead-in before enfortumab vedotin plus pembrolizumab improves outcomes versus standard next-line therapy in patients with metastatic, refractory urothelial or…
NCT07087860 Exploratory - New trial
Uterine (endometrial) cancer
Phase 1b Tirzepatide Study: Targets insulin, fat metabolism, and mTOR signaling.
In this randomized trial by UNC Lineberger Comprehensive Cancer Center, women with obesity, in situ, or Grade 1 endometrial cancer receive either 4 weeks of tirzepatide or no tirzepatide prior to surgery. Tirzepatide…
NCT07078838 Exploratory - New trial Spotlight
Multiple myeloma
Phase I Trial of GB1211 (Oral Galectin-3 Inhibitor) in Multiple Myeloma
This study is designed to evaluate the safety, tolerability, and optimal dosing of selvigaltin, a galectin-3 blocker, when combined with daratumumab-hyaluronidase, carfilzomib, and dexamethasone in patients with…
NCT07082270 First-in-human - New trial Spotlight
Head and neck cancer
Phase II Trial of Ivonescimab, a PD-1/VEGF bispecific antibody in resectable head and neck cancer
This phase II study by the University of Michigan Rogel Cancer Center evaluates neoadjuvant ivonescimab in patients with stage II-IV resectable head and neck cancer. Ivonescimab, a bispecific antibody targeting PD-1…
NCT07094685 Exploratory - New trial Spotlight
Stomach and esophageal cancer
Phase 3 Study of Ifinatamab Deruxtecan, a B7-H3 directed Topo1 toxin ADC, in ESCC
Researchers at Daiichi Sankyo are assessing ifinatamab deruxtecan versus investigator’s choice chemotherapy in a randomized, open-label Phase 3 trial for patients with unresectable advanced or metastatic esophageal…
NCT06644781 Registrational - New trial
Colorectal cancer
Phase 2 NALIRIFOX trial: liposomal irinotecan (topoisomerase I inhibitor) for advanced small intestine/appendiceal cancers
This trial assesses the safety and efficacy of first-line chemotherapy in advanced disease. The study uses an expansion arm receiving investigational NALIRIFOX regimen with nal-IRI (liposomal topoisomerase I…
NCT07060014 Exploratory - New trial
Thyroid cancer
Phase II Lenvatinib Trial: Multikinase Inhibitor for Radioactive Iodine Resistant Thyroid Cancer
In this open-label, randomized Phase II trial sponsored by Washington University School of Medicine, two dosing regimens of lenvatinib (a multikinase inhibitor) are compared to determine optimal dose delivery,…
NCT07092514 Exploratory - New trial
Kidney cancer
Phase 1 pilot: 89Zr-Girentuximab, anti-CAIX imaging agent for renal cell carcinoma PET evaluation.
This study evaluates whether PET imaging with 89Zr-Girentuximab, a CAIX-targeted agent, can detect residual or recurrent ccRCC in patients. In one group, participants undergo a PET scan post-injection, while the…
NCT07077083 Exploratory - New trial
Liver and bile duct cancer
Phase 1b study: Ipilimumab (CTLA-4 mAb) and Nivolumab (PD-1 mAb) with SBRT for HCC
This pilot trial, sponsored by University of Hawaii, evaluates response-adapted SBRT and subsequent surgery following preoperative ipilimumab and nivolumab in patients with borderline resectable hepatocellular…
NCT07075120 Exploratory - New trial
Sarcoma and GIST
Phase II Doxorubicin & Trabectedin Trial: DNA Synthesis and Tubulin Inhibition in Uterine Leiomyosarcoma
This Phase II single-arm study led by MD Anderson investigates the safety and efficacy of combining adjuvant doxorubicin (Topo II inhibitor) plus trabectedin (DNA-minor-groove binder) in patients with stage Ib-III…
NCT07076186 Exploratory - New trial
Lymphoma
Phase Ib Trial: Epcoritamab CD20/CD3 bispecific antibody for CNS lymphoma
This trial at Memorial Sloan Kettering evaluates the safety of epcoritamab, CD20/CD3 bispecific antibody, in combination with ibrutinib, a BTK inhibitor, in patients with relapsed/refractory primary or secondary…
NCT07082868 Exploratory - New trial
Colorectal cancer
Phase II Pembrolizumab PD-1 inhibitor plus Odetiglucan immune activator combination trial
Investigating safety and efficacy, Abramson Cancer Center at Penn Medicine is evaluating the combination of pembrolizumab—a PD-1 blocking monoclonal antibody—and odetiglucan, a glucan-based immune activator, in…
NCT07082439 Exploratory - New trial Spotlight
Multiple solid tumors
Phase 1 ALX2004 Antibody-Drug Conjugate Targeting EGFR in Advanced Solid Tumors
This phase 1 study evaluates ALX2004, an antibody drug conjugate targeting EGFR, in an open-label, multicenter trial featuring dose escalation, exploration, and expansion phases to determine the recommended phase 2…
NCT07085091 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1 trial of ERAS-4001, a pan-KRAS-targeted agent
This first-in-human open-label study evaluates the safety, tolerability, and preliminary efficacy of ERAS-4001 given orally as monotherapy and in combination with another investigational drug in a dose optimization…
NCT07021898 First-in-human - New trial
Multiple solid tumors
Phase 1 study of MK-4700 (investigational immune modulator) with PD-1 inhibitor pembrolizumab (mechanism undisclosed)
Merck Sharp & Dohme is sponsoring this open-label trial to evaluate escalating doses of MK-4700 as monotherapy and in combination with pembrolizumab in patients with advanced or metastatic solid tumors including…
NCT06894771 First-in-human - New trial
Multiple solid tumors
Phase 1 study of KQB168, an investigational anti-tumor agent, with pembrolizumab PD-1 inhibitor (mechanism undisclosed)
This open-label, multicenter dose escalation trial by Kumquat Biosciences Inc. evaluates oral KQB168 alone or with intravenous pembrolizumab to determine safe dosing and early efficacy in adults with advanced,…
NCT06994806 First-in-human - New trial
Multiple solid tumors
Phase 1 MOMA-341 study: Novel DNA damage response modulator in advanced solid tumors
This multi-center Phase 1 trial by MOMA Therapeutics evaluates the safety, tolerability, pharmacokinetics, and preliminary clinical activity of MOMA-341, a WRN helicase inhibitor, given as monotherapy or in…
NCT06974110 First-in-human - New trial
Multiple solid tumors
Pilot Phase RFA/BA+RT for metastatic spine lesions: Radiofrequency ablation & radiotherapy
This pilot randomized controlled study evaluates RFA with bone augmentation plus radiotherapy versus radiotherapy alone in patients with metastatic spine lesions from solid tumors (T5-L5). RFA employs…
NCT07090122 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.